| A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients (NCT01819818) | Janssen Korea, Ltd., Korea | 2011-05-23 |
| Brain Circuits in Schizophrenia and Smoking (NCT01369966) | National Institute on Drug Abuse (NIDA) | 2011-05-16 |
| A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia (NCT01545310) | Abbott | 2011-05-01 |
| The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia (NCT01339858) | Indiana University | 2011-05-01 |
| Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (NCT01323205) | Janssen Research & Development, LLC | 2011-05-01 |
| Effects of Metformin and Fish Oil on Treatment With Clozapine (NCT02140788) | Duke University | 2011-05-01 |
| Electronic Decision Support Systems for Smokers With Severe Mental Illness (NCT01412866) | Dartmouth-Hitchcock Medical Center | 2011-05-01 |
| A Study of Safety and Tolerability in Subjects With Schizophrenia (NCT01354353) | Denovo Biopharma LLC | 2011-05-01 |
| Optimization of Treatment and Management of Schizophrenia in Europe (NCT01248195) | Rene Kahn | 2011-05-01 |
| Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia (NCT01595503) | University of Michigan | 2011-05-01 |
| Can we Forget? Directed Forgetting and Embodied Cognition in Schizophrenia (NCT02538445) | Centre Hospitalier Universitaire de Saint Etienne | 2011-05-01 |
| Repetitive Transcranial Magnetic Stimulation (rTMS) and P50 Evoked Potential Component (NCT01466439) | University Hospital, Caen | 2011-05-01 |
| Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen (NCT01555814) | Birte Glenthoj | 2011-05-01 |
| Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia (NCT01363349) | BioLineRx, Ltd. | 2011-05-01 |
| Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238) (NCT01244828) | Organon and Co | 2011-04-05 |
| Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients (NCT01348100) | Novartis Pharmaceuticals | 2011-04-01 |
| Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia? (NCT01312272) | VA Greater Los Angeles Healthcare System | 2011-04-01 |
| To Rescue Cognition With Valaciclovir (NCT01364792) | University Medical Center Groningen | 2011-04-01 |
| Dental Status of Patients With Severe Mental Illness (NCT01315509) | Hadassah Medical Organization | 2011-04-01 |
| Dyad Oxytocin Study (DOS) (NCT02302209) | University of California, San Francisco | 2011-04-01 |
| Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia (NCT02354001) | The Alfred | 2011-04-01 |
| Single Ascending Dose Study of RBP-7000 (NCT02768649) | Indivior Inc. | 2011-04-01 |
| Magnetoencephalographic (MEG) Evidence for Novel Metaphor Processing Among Schizophrenic Patients (NCT01325363) | Shalvata Mental Health Center | 2011-04-01 |
| Feeling of Being in Control of One's Own Action (NCT01312649) | University Hospital, Strasbourg, France | 2011-04-01 |
| Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders (NCT01519557) | New York State Psychiatric Institute | 2011-04-01 |
| A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients (NCT01328093) | Denovo Biopharma LLC | 2011-04-01 |
| Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder (NCT01320982) | Sheba Medical Center | 2011-03-01 |
| Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL) (NCT01362426) | Janssen-Cilag Pty Ltd | 2011-03-01 |
| A Study of LY2140023 in Patients With Schizophrenia (NCT01307800) | Denovo Biopharma LLC | 2011-03-01 |
| A Comparison of Long-acting Injectable Medications for Schizophrenia (NCT01136772) | New York State Psychiatric Institute | 2011-03-01 |
| Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder (NCT01280305) | Sheba Medical Center | 2011-03-01 |
| Evaluation of Metamemory in Patients With Schizophrenia (NCT03338179) | University Hospital, Clermont-Ferrand | 2011-02-08 |
| An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia (NCT01634542) | Hoffmann-La Roche | 2011-02-01 |
| Illness Management and Recovery (IMR) in Danish Community Mental Health Centres (NCT01361698) | Amager Hospital | 2011-02-01 |
| CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness (NCT01149551) | US Department of Veterans Affairs | 2011-02-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia (NCT01234779) | Hoffmann-La Roche | 2011-02-01 |
| Perception Processing in Schizophrenia Patients and Normal Population (NCT01298349) | HaEmek Medical Center, Israel | 2011-02-01 |
| Relapse Prevention Study in Patients With Schizophrenia (NCT01291511) | Vanda Pharmaceuticals | 2011-02-01 |
| Cognitive Behavioral Therapy for Patients With an Early Psychosis (NCT01511406) | Oslo University Hospital | 2011-01-01 |
| Treatment Development Targeting Severe and Persistent Negative Symptoms (NCT01550666) | The University of Texas Health Science Center at San Antonio | 2011-01-01 |
| Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression (NCT02661789) | Gitte Moos Knudsen | 2011-01-01 |
| Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects (NCT01289080) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-01-01 |
| Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders (NCT01831986) | Sha'ar Menashe Mental Health Center | 2011-01-01 |
| A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307) (NCT01235520) | Hoffmann-La Roche | 2011-01-01 |
| Enhancing Synaptic Plasticity and Cognition in Schizophrenia (NCT01776112) | University Medical Center Goettingen | 2011-01-01 |
| Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia (NCT01295411) | Assistance Publique Hopitaux De Marseille | 2011-01-01 |
| Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia (NCT01315587) | University of Tehran | 2011-01-01 |
| Brain Circuits in Schizophrenia and Smoking (NCT01425684) | University of Maryland, Baltimore | 2010-12-20 |
| A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) (NCT01192867) | Hoffmann-La Roche | 2010-12-11 |
| Acute Psychological Effects of High Intensity Exercise With Schizophrenia (NCT01310998) | Norwegian University of Science and Technology | 2010-12-01 |
| Relative Effectiveness of Schizophrenia Therapy Study (NCT01245348) | Medco Health Solutions, Inc. | 2010-12-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306) (NCT01235585) | Hoffmann-La Roche | 2010-12-01 |
| A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects (NCT01299454) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2010-12-01 |
| Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels (NCT02652832) | Hôpital le Vinatier | 2010-12-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309) (NCT01192906) | Hoffmann-La Roche | 2010-12-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305) (NCT01235559) | Hoffmann-La Roche | 2010-12-01 |
| Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States (NCT01425671) | University of Maryland, Baltimore | 2010-11-30 |
| Multimodal MRI-guided rTMS to Treat Refractory Hallucinations (NCT01373866) | University Hospital, Lille | 2010-11-15 |
| The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy (NCT01215383) | Ziv Hospital | 2010-11-01 |
| Evaluation of Mirtazapine and Folic Acid for Schizophrenia: (NCT01263080) | Capital Medical University | 2010-11-01 |
| Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) (NCT01250847) | Severance Hospital | 2010-11-01 |
| Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia (NCT01213836) | AstraZeneca | 2010-11-01 |
| Paliperidone Palmitate Flexible Dosing in Schizophrenia (NCT01281527) | Janssen-Cilag International NV | 2010-11-01 |
| An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia (NCT02640911) | Shanghai Mental Health Center | 2010-11-01 |
| Neurophysiological Targets for Cognitive Training in Schizophrenia (NCT00923078) | VA Office of Research and Development | 2010-11-01 |
| A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder (NCT01116830) | Hoffmann-La Roche | 2010-11-01 |
| An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (NCT01309373) | Janssen-Cilag, S.A. | 2010-11-01 |
| Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics (NCT01246128) | National Institute on Drug Abuse (NIDA) | 2010-10-31 |
| An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia (NCT01175135) | Pfizer | 2010-10-01 |
| Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan (NCT01249079) | China Medical University Hospital | 2010-10-01 |
| Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan (NCT01357005) | Far Eastern Memorial Hospital | 2010-10-01 |
| A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia (NCT01258920) | Janssen Pharmaceutical K.K. | 2010-10-01 |
| Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia (NCT01420575) | VA Nebraska Western Iowa Health Care System | 2010-10-01 |
| Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness (NCT01244854) | VA Office of Research and Development | 2010-10-01 |
| A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia (NCT01212575) | AstraZeneca | 2010-10-01 |
| Adult Study Oxytocin - Behavioral (NCT02567032) | University of California, San Francisco | 2010-10-01 |
| Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis (NCT01216891) | Research Foundation for Mental Hygiene, Inc. | 2010-10-01 |
| An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia (NCT01299389) | Janssen Pharmaceutical K.K. | 2010-10-01 |
| Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia (NCT01222793) | National Institute on Drug Abuse (NIDA) | 2010-09-26 |
| DAAOI-1 Treatment for Treatment-resistant Schizophrenia (NCT01390376) | China Medical University Hospital | 2010-09-01 |
| PHARMO Institute Seroquel Safety Study (NCT01342120) | AstraZeneca | 2010-09-01 |
| Effectiveness of Ziprasidone for Patients With Schizophrenia (NCT01198353) | Soonchunhyang University Hospital | 2010-09-01 |
| Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations (NCT01181960) | Janssen Scientific Affairs, LLC | 2010-08-01 |
| Salsalate for Insulin Resistance in Schizophrenia (NCT01182727) | University of Maryland, Baltimore | 2010-08-01 |
| Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning (NCT01161277) | Oslo University Hospital | 2010-08-01 |
| Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia (NCT01242371) | Sheppard Pratt Health System | 2010-08-01 |
| Switching to Iloperidone From Other Antipsychotics in Schizophrenia (NCT01207414) | Novartis | 2010-08-01 |
| A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (NCT01143090) | Sumitomo Pharma America, Inc. | 2010-08-01 |
| Adult Oxytocin Study (NCT02577575) | University of California, San Francisco | 2010-08-01 |
| Mindfulness-based Illness Management Program for Schizophrenia (NCT01667601) | The Hong Kong Polytechnic University | 2010-08-01 |
| Randomized Double Blind Placebo Control Study in Patients with Schizophrenia (NCT01602029) | Pakistan Institute of Living and Learning | 2010-08-01 |
| Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital (NCT01193166) | Ortho-McNeil Janssen Scientific Affairs, LLC | 2010-08-01 |
| Waist Circumference Measurements in Schizophrenic Patients (NCT01243034) | Changhua Christian Hospital | 2010-08-01 |
| Yoga as Cognitive Remediation in Schizophrenia (NCT01879709) | Dr. Ram Manohar Lohia Hospital | 2010-08-01 |
| Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States (NCT03257592) | Johns Hopkins University | 2010-08-01 |
| Benefits Management for People With Psychiatric Disabilities (NCT01329393) | Yale University | 2010-08-01 |
| Reduction of Cardiovascular Risk in Severe Mental Illness (NCT01182012) | Consorci Hospitalari de Vic | 2010-08-01 |
| Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia (NCT01160679) | AstraZeneca | 2010-08-01 |
| A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (NCT01942148) | Otsuka Pharmaceutical Co., Ltd. | 2010-08-01 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1) (NCT01206517) | Organon and Co | 2010-07-18 |